MedTrace Logo

Vitamin C to Reduce Morning Cardiovascular Risk

NCT03290612 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-03-23

No results posted yet for this study

Summary

This study will test the efficacy of Vitamin C to counteract morning cardiovascular (CV) risk markers in a randomized, double blind, placebo controlled crossover pilot study. The participants will also perform morning typical behaviors such as arousal from sleep, change in posture (getting out of bed) and mild intensity physical activity; identical to the stressors encountered in everyday life. Primary dependent variables are markers of cardiovascular risk including vascular endothelial function and oxidative stress.

Conditions

  • Cardiovascular Risk Factor

Interventions

DIETARY_SUPPLEMENT

Vitamin C

1.5g Ascorbic Acid

OTHER

Placebo

Inactive placebo to mimic 1.5g ascorbic acid.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Saurabh S Thosar, PhD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-13
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03290612 on ClinicalTrials.gov